Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study
机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China.[2]Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.[3]Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.[4]National Clinical Research Centre for Hematologic Disease, Beijing, China.[5]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.华中科技大学同济医学院附属同济医院[6]Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.[7]Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China.南方医科大学珠江医院[8]Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.江苏省人民医院[9]Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.[10]Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China.[11]Department of Hematology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China.[12]Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.四川省人民医院[13]Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China.[14]Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, Yunnan, China.[15]Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Myeloid sarcoma (MS) is a rare hematological neoplasm with poor prognosis, posing a significant clinical challenge due to the absence of effective and standardized treatments. We conducted a retrospective analysis of 162 MS patients treated at 12 centers to compare outcomes between intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our analysis revealed that allo-HSCT demonstrated superior overall survival (OS) within the initial 36 months compared to intensive chemotherapy alone (p = 0.037). However, beyond 36 months (36-60 months), a reverse trend was observed (p = 0.056). Subgroup analysis revealed potential benefit for isolated MS patients with allo-HSCT, but not for those with leukemic MS. Additionally, in patients achieving first complete remission (CR1) after induction chemotherapy, allo-HSCT did not significantly improve 5-year OS compared with intensive chemotherapy alone (p = 0.25). Conversely, allo-HSCT significantly improved 5-year OS in non-CR1 patients (p < 0.001). Notably, HLA-matched HSCT and haploidentical HSCT showed comparable outcomes in terms of OS, disease-free survival, and cumulative incidence of relapse. In conclusion, allo-HSCT improved outcomes for MS patients within 36 months of disease onset, and haploidentical HSCT emerged as a viable treatment option for patients without matched donors.
基金：
National Key Research and Development Program of China [2023YFC2507803]; Key Program of National Natural Science Foundation of China [82230004]; Beijing Natural Science Foundation [7242154]
第一作者机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China.[2]Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.[3]Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.[4]National Clinical Research Centre for Hematologic Disease, Beijing, China.
共同第一作者：
通讯作者：
通讯机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China.[2]Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.[3]Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.[4]National Clinical Research Centre for Hematologic Disease, Beijing, China.
推荐引用方式(GB/T 7714)：
Sun Jie,Zhang Yi-Cheng,Wei Jia,et al.Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study[J].BONE MARROW TRANSPLANTATION.2024,doi:10.1038/s41409-024-02485-y.
APA：
Sun, Jie,Zhang, Yi-Cheng,Wei, Jia,Xu, Ya-Jing,Zhang, Yue...&Zhang, Xiao-Hui.(2024).Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study.BONE MARROW TRANSPLANTATION,,
MLA：
Sun, Jie,et al."Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study".BONE MARROW TRANSPLANTATION .(2024)
